Evoke Pharma Inc (NASDAQ:EVOK) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday.
According to Zacks, “Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company’s lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. “
EVOK has been the topic of a number of other research reports. HC Wainwright set a $9.00 target price on Evoke Pharma and gave the company a “buy” rating in a report on Tuesday. ValuEngine raised Evoke Pharma from a “strong sell” rating to a “sell” rating in a report on Friday, July 7th. Finally, FBR & Co reaffirmed a “buy” rating and issued a $9.00 target price on shares of Evoke Pharma in a report on Thursday, May 18th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $7.25.
Evoke Pharma (NASDAQ:EVOK) remained flat at $2.58 during trading on Thursday. The company had a trading volume of 72,518 shares. The stock’s 50-day moving average is $2.44 and its 200-day moving average is $2.72. The company’s market capitalization is $39.70 million. Evoke Pharma has a 1-year low of $1.35 and a 1-year high of $4.55.
Evoke Pharma (NASDAQ:EVOK) last released its earnings results on Monday, August 14th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.15. During the same quarter in the previous year, the business earned ($0.41) earnings per share. Equities analysts anticipate that Evoke Pharma will post ($0.86) EPS for the current fiscal year.
WARNING: This article was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/2829553/evoke-pharma-inc-evok-downgraded-by-zacks-investment-research.html.
Several hedge funds have recently made changes to their positions in EVOK. State Treasurer State of Michigan raised its stake in shares of Evoke Pharma by 62.2% in the first quarter. State Treasurer State of Michigan now owns 291,966 shares of the specialty pharmaceutical company’s stock valued at $905,000 after buying an additional 111,966 shares during the last quarter. Sphera Funds Management LTD. purchased a new stake in shares of Evoke Pharma during the first quarter valued at $1,550,000. Finally, Vanguard Group Inc. raised its stake in shares of Evoke Pharma by 15.1% in the second quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock valued at $1,341,000 after buying an additional 68,544 shares during the last quarter. 12.37% of the stock is currently owned by institutional investors.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evoke Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.